Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: A national population-based study

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 8, 2015, Pages 990-999

  Chhaya, V ^a   Pollok, R C G ^a   Cecil, E ^b   Subramanian, V ^c   Curcin, V ^d   Majeed, A ^b   Saxena, S ^b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; MESALAZINE; STEROID; IMMUNOLOGIC FACTOR; PURINE DERIVATIVE;

ADOLESCENT; ADULT; APPENDECTOMY; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFANT; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK REDUCTION; SMOKING; SURGICAL RISK; TIME TO TREATMENT; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; GREAT BRITAIN; NEWBORN; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; EARLY MEDICAL INTERVENTION; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOLOGIC FACTORS; INFANT; INFANT, NEWBORN; MALE; PURINES; RISK FACTORS; YOUNG ADULT;

EID: 84941734607     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13361     Document Type: Article

References (43)

1. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM,. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17: 423-39.
2. Molodecky NA, Soon IS, Rabi DM, et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.
3. Van Limbergen J, Russell RK, Drummond HE, et al., Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114-22.
4. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al., The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009; 104: 2080-8.
5. Rieder F, Reinisch W,. Thiopurines and the natural course of Crohn's disease: did we finally find the right therapeutic target? Am J Gastroenterol 2014; 109: 1037-40.
6. Ruemmele FM, Veres G, Kolho KL, et al., Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014; 8: 1179-207.
7. Turner D, Levine A, Escher JC, et al., Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012; 55: 340-61.
8. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F,. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
9. Magro F, Rodrigues-Pinto E, Coelho R, et al., Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol 2014; 109: 1026-36.
10. Ramadas A, Gunesh S, Thomas G, Williams G, Hawthorne A,. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-6.
11. Lakatos PL, Golovics PA, David G, et al., Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012; 107: 579-88.
12. Chatu S, Subramanian V, Saxena S, Pollok RC,. The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 23-34.
13. Cosnes J, Bourrier A, Laharie D, et al., Earl y administration of azathioprine versus conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology 2013; 145: 758-65.
14. Panés J, López-Sanromán A, Bermejo F, et al., Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013; 145: 766-74.
15. Chatu S, Saxena S, Subramanian V, et al., The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn's disease: National UK population-based study 1989-2010. Am J Gastroenterol 2014; 109: 409-16.
16. Chhaya V, Saxena S, Cecil E, et al., The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009. Aliment Pharmacol Ther 2015; 41: 89-98.
17. Chhaya V, Saxena S, Cecil E, et al., Impact of timing and duration of thiopurine treatment on first perianal surgery in Crohn's disease: UK population-based. Inflamm Bowel Dis 2015; 21: 385-91.
18. Khan NF, Harrison SE, Rose PW,. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pr 2010; 60: e128-36.
19. Lewis JD, Brensinger C, Bilker WB, Strom BL,. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002; 11: 211-8.
20. Lewis JD, Aberra FN, Lichtenstein GR, Bilker WB, Brensinger C, Strom BL,. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology 2004; 126: 665-73.
21. Levine A, Griffiths A, Markowitz J, et al., Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314-21.
22. Samuel S, Ingle SB, Dhillon S, et al., Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 2013; 19: 1858-66.
23. Gupta N, Cohen SA, Bostrom AG, et al., Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology 2006; 130: 1069-77.
24. Punati J, Markowitz J, Lerer T, et al., Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis 2008; 14: 949-54.
25. Schaefer ME, Machan JT, Kawatu D, et al., Factors that determine risk for surgery in pediatric patients with Crohn's disease. Clin Gastroenterol Hepatol 2010; 8: 789-94.
26. Louis E, Collard A, Oger A, et al., Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-82.
27. Cosnes J, Cattan S, Blain A, et al., Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50.
28. Gao X, Yang R, Chen M, et al., Risk factors for surgery and postoperative recurrence: analysis of a south China cohort with Crohn's disease. Scand J Gastroenterol 2012; 47: 1181-91.
29. Nguyen GC, Nugent Z, Shaw S, Bernstein CN,. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011; 141: 90-7.
30. Kariyawasam VC, Selinger CP, Katelaris PH, et al., Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease. Inflamm Bowel Dis 2014; 20: 1382-90.
31. Vernier-Massouille G, Balde M, Salleron J, et al., Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106-13.
32. Targownik LE, Singh H, Nugent Z, Bernstein CN,. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012; 107: 1228-35.
33. Benchimol EI, Mack DR, Nguyen GC, et al., Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology 2014; 147: 1-11.
34. Malaty HM, Abraham BP, Mehta S, Garnett EA, Ferry GD,. The natural history of ulcerative colitis in a pediatric population: a follow-up population-based cohort study. Clin Exp Gastroenterol 2013; 6: 77-83.
35. Bernell O, Lapidus A, Hellers G,. Risk factors for surgery and postoperative recurrence in crohn's disease. Ann Surg 2000; 231: 38-45.
36. Munkholm P, Langholz E, Davidsen M, Binder V,. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716-23.
37. Cosnes J, Seksik P, Nion-Larmurier I, Beaugerie L, Gendre J,. Prior appendectomy and the phenotype and course of Crohn's disease. World J Gastroenterol 2006; 12: 1235-42.
38. Butow P, Palmer S, Pai A, Goodenough B, Luckett T, King M,. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol 2010; 28: 4800-9.
39. NICE Technology Appraisal Guidance 187. Infliximab (review) and adalimumab for the treatment of Crohn's disease. May 2010. Available at: www.nice.org.uk/guidance/TA187. Accessed 01/04/2015
40. NICE Technology Appraisal Guidance 140. Infliximab for subacute manifestations of ulcerative colitis. Feb 2011. Available at: www.nice.org.uk/guidance/TA140. Accessed 01/04/2015
41. Bardhan KD, Simmonds N, Royston C, Dhar A, Edwards CM,. A United Kingdom inflammatory bowel disease database: making the effort worthwhile. J Crohns Colitis 2010; 4: 405-12.
42. Pappa HM, Semrin G, Walker TR, Grand RJ,. Pediatric inflammatory bowel disease. Curr Opin Gastroenterol 2004; 20: 333-40.
43. Kugathasan S, Saubermann LJ, Smith L, et al., Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007; 56: 1696-705.